Machado-Joseph disease, also known as spinocerebellar ataxia 3, (MJD/SCA3) is a rare disease characterized by varied phenotypic features and progressive neurodegeneration. It is caused by a trinucleotide repeat expansion (CAG) related to the mutation in the ATXN3 gene located at chromosome 14q32.1 [1]. Clinical presentation consists of motor, as well as, non-motor manifestations. Motor manifestations are noticed initially between the age of 30 and 40 years and they include cerebellar ataxia, gait instability, incoordination of limb movements, and intentional tremor [2]. Spasticity is a common feature with lower limbs being more frequently affected [2]. Later, other motor problems like dysphagia, dysarthria, and truncal ataxia start to develop. Diplopia is a common ocular complaint [2]. Dystonia and parkinsonism are two movement disorders which are frequently noticed in MJD/SCA3 along with peripheral neuropathy, tactile and proprioceptive hypoesthesia [3] [4] [5]. Non-motor manifestations include chronic pain, cramps, fatigue, sleep disorders, and depression, while autonomic symptoms like nocturia, urinary incontinence, cold intolerance and hypohidrosis may also be present [6]. A majority of MJD/SCA3 patients have excessive daytime sleepiness with impaired nocturnal sleep [7], insomnia [8], and restless legs syndrome. Sleep disorders are seen more frequently in older adults with a long-standing disease. About half of the patients complain of chronic pain, especially in the lumbar region [9]. Minor cognitive and behavioral difficulties, but not frank dementia, are noticed in MJD/SCA3 patients [10].

Three types of MJD/SCA3 have been identified with onset and severity being their differentiating features:

• Type I MJD/SCA3 has an early onset in the 1st to the 3rd decades with a rapid progression. It is characterized by spastic dystonia, ataxia, athetosis, ophthalmoplegia, and exophthalmos. Mental and intellectual abilities are most frequently normal.

• Type II MJD/SCA3 has an onset between the 2nd and 5th decade with a slower progression. Ataxia and limb incoordination are its characteristic features along with spasticity.

• Type III MJD/SCA3 presents between the 4th and 7th decades, has the slowest progression and is characterized by ataxia with muscular atrophy and motor polyneuropathy. Analgesia, paresthesia, incoordination and diabetes are other common features of this type.

Clinical presentation of MJD/SCA3 resembles other neurologic disorders like Parkinson's disease and multiple sclerosis. Therefore diagnosis based on clinical features, family history, and genetic testing, requires an experienced neurologist for interpretation. A family history of neurological disorders should be inquired about during the preliminary interview. Predictive genetic testing in the absence of symptoms can be performed in suspected cases with a positive family history [11]. During the physical examination, gaze-evoked nystagmus, abnormal saccades, decreased smooth pursuit gain, impaired vestibulo-ocular reflex, and supranuclear vertical gaze palsy may be noticed [12]. Lid retraction and decreased blinking may lead to the appearance of “bulging eyes" which is characteristic of MJD/SCA3 [2]. The diagnostic test to detect MJD/SCA3 is the direct determination of the number of abnormal CAG triplets in the DNA of affected patients using genetic testing which is available in specialized laboratories.

Neuroimaging studies like magnetic resonance imaging (MRI) help to demonstrate the extent of neural degeneration. MRI may be normal in the early stages of MJD/SCA3 but typical findings include brainstem and cerebellar atrophy [10]. Single-photon emission computed tomography (SPECT) studies of the brain have shown poor perfusion in the parietal lobes, inferior portion of the frontal lobes, medial and lateral portions of the temporal lobes, basal ganglia, and cerebellar hemispheres and vermis [13]. Magnetic resonance spectroscopy (MRS) of the deep white matter has demonstrated changes indicative of axonal dysfunction, although MRI in the same study did not reveal any abnormalities [14].

Currently, there is no cure for Machado-Joseph Disease. Treatment focuses on managing symptoms and improving quality of life. This may include:

• Physical therapy: To improve balance, coordination, and muscle strength.
• Speech therapy: To address speech and swallowing difficulties.
• Medications: To manage symptoms such as muscle stiffness, pain, and sleep disturbances.
• Occupational therapy: To assist with daily activities and maintain independence.

Supportive care from a multidisciplinary team is essential for addressing the diverse needs of individuals with MJD.

The prognosis for Machado-Joseph Disease varies depending on the age of onset and the severity of symptoms. Generally, the disease progresses over several decades, leading to increasing disability. Life expectancy may be reduced, but many individuals live into their 60s or 70s. Early intervention and supportive care can help manage symptoms and improve quality of life.

Machado-Joseph Disease is caused by a genetic mutation in the ATXN3 gene, which provides instructions for making a protein called ataxin-3. This mutation leads to an abnormal expansion of a DNA segment known as a CAG repeat. The longer the repeat, the earlier the onset and more severe the symptoms. MJD is inherited in an autosomal dominant pattern, meaning a single copy of the mutated gene from an affected parent can cause the disease.

Machado-Joseph Disease is the most common type of spinocerebellar ataxia worldwide, though it remains rare. It is more prevalent in certain populations, such as those of Portuguese, Japanese, and Brazilian descent. The prevalence varies, with estimates ranging from 0.3 to 2 per 100,000 individuals in the general population.

The pathophysiology of Machado-Joseph Disease involves the accumulation of abnormal ataxin-3 protein in nerve cells, leading to their dysfunction and death. This primarily affects the cerebellum, which is responsible for coordinating movement, and other parts of the brain and spinal cord. The exact mechanisms by which the mutant protein causes cell damage are not fully understood, but it is believed to involve disruptions in protein degradation, cellular stress responses, and mitochondrial function.

As Machado-Joseph Disease is a genetic disorder, there is no known way to prevent it. However, genetic counseling can provide valuable information for individuals with a family history of the disease. This can help them understand their risk and make informed decisions about family planning. Prenatal testing and preimplantation genetic diagnosis are options for those who wish to avoid passing the mutation to their children.

Machado-Joseph Disease is a rare, inherited neurodegenerative disorder characterized by progressive ataxia and other neurological symptoms. It is caused by a genetic mutation in the ATXN3 gene and is inherited in an autosomal dominant pattern. While there is no cure, supportive care and symptom management can improve quality of life. Genetic counseling is important for individuals with a family history of the disease.

If you or a loved one has been diagnosed with Machado-Joseph Disease, it's important to understand that you are not alone. This condition affects individuals differently, and a range of therapies and support services are available to help manage symptoms and maintain quality of life. Working closely with a healthcare team, including neurologists, physical therapists, and other specialists, can provide comprehensive care tailored to your needs. Genetic counseling can also offer guidance and support for family planning decisions.

1. Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet. 1994;8:221–228
2. Coutinho P. Doença de Machado-Joseph: Estudo Clínico, Patológico e Epidemiologico de uma Doença Neurológica de Origem Portuguesa. Porto, Portugal: Tipografia Nunes Ltda; 1994.
3. Rosenberg RN. Machado-Joseph disease: an autosomal dominant motor system degeneration. Mov Disord. 1992;7:193–203.
4. Jardim LB, Pereira ML, Silveira I, Ferro A, Sequeiros J, Giugliani R. Neurologic findings in Machado-Joseph disease: relation with disease duration, subtypes, and (CAG)n. Arch Neurol. 2001;58:899–904.
5. Klockgether T, Schols L, Abele M, et al. Age-related axonal neuropathy in spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD). J Neurol Neurosurg Psychiatry. 1999;66:222–224.
6. Yeh TH, Lu CS, Chou YH, et al. Autonomic dysfunction in Machado-Joseph disease. Arch Neurol. 2005;62:630–636.
7. Friedman JH, Fernandez HH, Sudarsky LR. REM behavior disorder and excessive daytime somnolence in Machado-Joseph disease (SCA-3) Mov Disord. 2003;18:1520–1522.
8. D’Abreu A, Franca MC Jr, Conz L, et al. Sleep symptoms and their clinical correlates in Machado-Joseph Disease. Acta Neurol Scand. 2009;119(4):277–280.
9. Franca MC Jr, D’Abreu A, Friedman JH, Nucci A, Lopes-Cendes I. Chronic pain in Machado-Joseph disease: a frequent and disabling symptom. Arch Neurol. 2007;64:1767–1770.
10. D'Abreu A, Franca MC, Paulson HL, Lopes-Cendes I. Caring for Machado-Joseph disease: current understanding and how to help patients. Parkinsonism Relat. Disord. 2010;16(1):2
11. Cannella M, Simonelli M, D’Alessio C, et al. Presymptomatic tests in Huntington’s disease and dominant ataxias. Neurol Sci. 2001;22:55–56.
12. Gordon CR, Joffe V, Vainstein G, Gadoth N. Vestibulo-ocular arreflexia in families with spinocerebellar ataxia type 3 (Machado-Joseph disease) J Neurol Neurosurg Psychiatry. 2003;74:1403–1406.
13. Etchebehere EC, Cendes F, Lopes-Cendes I, et al. Brain single-photon emission computed tomography and magnetic resonance imaging in Machado-Joseph disease. Arch Neurol. 2001;58:1257–1263.
14. D’Abreu A, França M, Jr, Appenzeller S, et al. Axonal Dysfunction in the Deep White Matter in Machado-Joseph Disease. J Neuroimaging. 2009;19(1):9-12.